JP2008524235A - オクトレオチド化合物の徐放性送達処方物 - Google Patents

オクトレオチド化合物の徐放性送達処方物 Download PDF

Info

Publication number
JP2008524235A
JP2008524235A JP2007546882A JP2007546882A JP2008524235A JP 2008524235 A JP2008524235 A JP 2008524235A JP 2007546882 A JP2007546882 A JP 2007546882A JP 2007546882 A JP2007546882 A JP 2007546882A JP 2008524235 A JP2008524235 A JP 2008524235A
Authority
JP
Japan
Prior art keywords
octreotide
implant
atrigel
composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524235A5 (https=
Inventor
スティーブン エル． ウォーレン，
エリック ダデイ，
リチャード エル． ダン，
ジョン ミルトン ダウニング，
エレン チ リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2008524235A publication Critical patent/JP2008524235A/ja
Publication of JP2008524235A5 publication Critical patent/JP2008524235A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2007546882A 2004-12-15 2005-12-15 オクトレオチド化合物の徐放性送達処方物 Pending JP2008524235A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627304P 2004-12-15 2004-12-15
PCT/US2005/045346 WO2006065951A2 (en) 2004-12-15 2005-12-15 Sustained delivery formulations of octreotide compounds

Publications (2)

Publication Number Publication Date
JP2008524235A true JP2008524235A (ja) 2008-07-10
JP2008524235A5 JP2008524235A5 (https=) 2009-01-29

Family

ID=36588524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546882A Pending JP2008524235A (ja) 2004-12-15 2005-12-15 オクトレオチド化合物の徐放性送達処方物

Country Status (6)

Country Link
US (1) US20090092650A1 (https=)
EP (1) EP1838285A2 (https=)
JP (1) JP2008524235A (https=)
AU (1) AU2005316545A1 (https=)
CA (1) CA2590696A1 (https=)
WO (1) WO2006065951A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512147A (ja) * 2008-12-15 2012-05-31 ノバルティス アーゲー 一定して高い曝露レベルを有するオクトレオチドのデポー製剤
JP2013522239A (ja) * 2010-03-12 2013-06-13 サーモディクス，インコーポレイテッド 注射用薬物送達システム
JP2018522906A (ja) * 2015-08-03 2018-08-16 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SI2079767T1 (sl) * 2006-10-11 2015-01-30 Tolmar Therapeutics, Inc. Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
CN102112107A (zh) 2008-06-03 2011-06-29 托马医疗科技公司 具有改进的释放动力学特征的控制释放共聚物制剂
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) * 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9155745B2 (en) * 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
US8827884B2 (en) 2009-08-06 2014-09-09 Koninklijke Philips N.V. Oncology therapies employing radioactive seeds
WO2011087496A1 (en) * 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
JP6294885B2 (ja) 2012-08-30 2018-03-14 エーティーアールピー ソリューションズ インコーポレイテッドＡＴＲＰ Ｓｏｌｕｔｉｏｎｓ，Ｉｎｃ． 星形高分子、星形高分子組成物および星形高分子の製造方法
CN105263978B (zh) 2013-02-04 2018-04-17 Atrp解决方案公司 耐盐星形大分子
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2956431C (en) 2014-07-03 2023-01-31 ATRP Solutions, Inc. Surfactant-compatible star macromolecules
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
TW201720446A (zh) * 2015-11-13 2017-06-16 Ｏｈｒ製藥公司 非典型脈絡膜新生血管（ｃｎｖ）之大小做為以角鯊胺治療之預測子
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
AU2018448134A1 (en) * 2018-10-29 2021-05-27 Pujing Chemical Industry Co., Ltd Polyglycolide copolymer and preparation thereof
AU2018448021A1 (en) * 2018-10-29 2021-05-27 Pujing Chemical Industry Co., Ltd Heat and aging resistant polyglycolide copolymer and composition thereof
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN113318218A (zh) * 2021-07-20 2021-08-31 国药一心制药有限公司 一种醋酸奥曲肽注射液及其制备工艺
CN120131956A (zh) * 2023-12-11 2025-06-13 中山大学中山眼科中心 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043222A2 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
JP2004516263A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
WO2004045633A2 (en) * 2002-11-19 2004-06-03 Novartis Ag Pharmaceutical composition comprising octreotide microparticles
JP2004517146A (ja) * 2001-01-26 2004-06-10 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 生物活性物質カプセル化生分解性高分子の微粒子および該微粒子を含有する徐放性医薬配合物
WO2004078922A2 (en) * 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
EP2455072A1 (en) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516263A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
JP2004517146A (ja) * 2001-01-26 2004-06-10 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 生物活性物質カプセル化生分解性高分子の微粒子および該微粒子を含有する徐放性医薬配合物
WO2004043222A2 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
WO2004045633A2 (en) * 2002-11-19 2004-06-03 Novartis Ag Pharmaceutical composition comprising octreotide microparticles
WO2004078922A2 (en) * 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512147A (ja) * 2008-12-15 2012-05-31 ノバルティス アーゲー 一定して高い曝露レベルを有するオクトレオチドのデポー製剤
JP2013522239A (ja) * 2010-03-12 2013-06-13 サーモディクス，インコーポレイテッド 注射用薬物送達システム
JP2018522906A (ja) * 2015-08-03 2018-08-16 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
US11779589B2 (en) 2015-08-03 2023-10-10 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US12447158B2 (en) 2015-08-03 2025-10-21 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs

Also Published As

Publication number Publication date
CA2590696A1 (en) 2006-06-22
WO2006065951A2 (en) 2006-06-22
US20090092650A1 (en) 2009-04-09
AU2005316545A1 (en) 2006-06-22
WO2006065951A3 (en) 2006-10-19
EP1838285A2 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
JP2008524235A (ja) オクトレオチド化合物の徐放性送達処方物
JP7297116B2 (ja) 前立腺癌を治療するための組成物
CN104248623B (zh) 使用非水性载体的持续释放制剂
AU2009268480B2 (en) Delivery of dry formulations of octreotide
KR101466933B1 (ko) 펩타이드의 지속 방출 전달을 위한 의약 조성물
KR20140105527A (ko) 강력한 방출-조절된 펩티드 제형
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
EP2164473B1 (en) An extended-release composition comprising a somatostatin derivative in microparticles
US20250018004A1 (en) Pharmaceutical Compositions having a Selected Release Duration
CN110101846A (zh) 一种低突释率的索玛鲁肽微球及其制备方法
US20250319099A1 (en) Method of administering a hormone encapsulated by a hydrogel with a dual chamber syringe
CN118103030A (zh) 可注射的高浓度药物制剂及其制造和使用方法
JP2001510811A (ja) 生物活性物質を標的に供給するための重合体ベースの薬剤組成物
WO2009148583A2 (en) Method for improvement of octreotide bioavailability
Rathi et al. ReGel depot technology
CA3084339C (en) Pharmaceutical compositions having a selected release duration
EP4721730A1 (en) Pharmaceutical composition comprising sustained-release microsphere comprising cagrilintide or pharmaceutically acceptable salt thereof and preparation method therefor
Fan et al. Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits
KR20250035949A (ko) 성장호르몬 마이크로니들 제조용 점액 조성물, 이를 이용하여 제조되는 성장호르몬 마이크로니들 구조체, 상기 마이크로니들 구조체를 포함하는 마이크로니들 패치 및 마이크로어레이
Cunningham et al. Formulation of depot delivery systems
NZ766167B2 (en) Pharmaceutical compositions having a selected release duration
HK1141248A (en) An extended-release composition comprising a somatostatin derivative in microparticles
HK1141248B (en) An extended-release composition comprising a somatostatin derivative in microparticles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120120